IBMC
ibmc01 ibmc02 ibmc03 ibmc04 ibmc05 ibmc06 ibmc07 ibmc08 ibmc09 ibmc10 ibmc11 ibmc12
jQuery Image Slider by WOWSlider.com v2.0
web del Instituto de Biología Molecular y Celular

Technology transfer


One unique aspect of the IBMC is its commitment to the transfer of technology to the private sector and the application of laboratory knowledge to the clinical sector. Since its creation, the IBMC has maintained a very active transfer of technology, superior to that of many other institutes at the national level, making the IBMC a model in the transfer of basic science to the industrial and clinical areas. The following table summarises the translational activities since the creation of the IBMC. Due to the unique character of these activities we have decided to include the entire period so that the amount and diversity of these achievements can be better appreciated.

Sin título 1

A. transfer of technology (1998-2011)

 

A.1 activities in collaboration with private companies

 

Number

Funding

1.PETRI/TRACE Projects

3

€212,780

2.R&D Contracts

60

€4,492,894

3.Services offered

21

€66,173

 

A.2 PATENTS

1. Requested

29

2. Extended via the Patent Cooperation Treaty

17

3. Awarded and administered by the World Intellectual Property Organisation

15

4. Awarded

10

5. Licensed

12

6. Commercial Use

12

7. Marketed Products

LyTag resin, LyTag2Phase, Argireline, Chromabright, Bodyfensin, Leuphasyl, Cartixan-4, Plx, Hypoxdermin, Melatime, Thermostressin, Diffuporine, Adifyline, Silusyne

 

A.3 Creation of spin-off companies

Company

IBMC's share

Company number

Year

DiverDrugs

5.38%

B-61905725

1999

Nutracitrus

7.50%

B-73263154

2003

 

A.4 PARTICIPATION IN COMPANIES' SCIENTIFIC COMMITTEES

Company

Period

DiverDrugs

1999-present

Lipotec

1998-present

CP Pharm

2006-present

Nutracitrus

2003-present

LipoPharm

2007-present

Bioarray

2008-present

BCN Peptides

2008-present

Monteloeder

2001-present

New Development in Nutraceuticals

2004-present

Quimicas del Vinalopo

2004-present

Endemic Biotech

2006-present

 

A.5 IBMC-UMH-COMPANIES MIXED UNITS

Company

Period

Lipotec/Diverdrugs

2000-present

JBT

2001-present

 

B. TRANSLATIONAL ACTIVITIES

 

Number

Period

1. Agreements in hospitals

Elche General Hospital

Alicante General Hospital

Elche Hospital Foundation

3

 

1

1

 

1

 

 

2001-present

2003-present

 

2009-present

2. Projects with hospital personnel cooperation

14

1998-present

3. Joint publications with hospital personnel

16

1998-present

4. Seminars/joint workshops

1

2008

5. PhD programs

1

1998-present

6. Scientific networks

1

2007-2010

7. HTS platform

1

1999-present

8. Skin Research Platform

1

2010-present